Cite
HARVARD Citation
Burmester, G. et al. (n.d.). FRI0216 Long-Term Safety and Efficacy of Mavrilimumab, A Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-Alpha Monoclonal Antibody, in Patients with Rheumatoid Arthritis. Annals of the rheumatic diseases. p. 510. [Online].